These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 30609236

  • 1. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
    Giugliano D, Meier JJ, Esposito K.
    Diabetes Obes Metab; 2019 May; 21(5):1081-1087. PubMed ID: 30609236
    [Abstract] [Full Text] [Related]

  • 2. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K.
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
    Rajani A, Sahay M, Bhattacharyya A, Amar A.
    Diabet Med; 2020 Apr; 37(4):593-601. PubMed ID: 32012347
    [Abstract] [Full Text] [Related]

  • 6. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ.
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C, Mudaliar S.
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [Abstract] [Full Text] [Related]

  • 10. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
    Singh AK, Singh R.
    Indian J Endocrinol Metab; 2019 Feb; 23(2):175-183. PubMed ID: 31161099
    [Abstract] [Full Text] [Related]

  • 14. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME, Kosiborod M.
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
    Bailey CJ, Marx N.
    Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
    Scheen AJ.
    Diabetes Res Clin Pract; 2017 May; 127():224-237. PubMed ID: 28402902
    [Abstract] [Full Text] [Related]

  • 17. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
    Pan X, Xu S, Li J, Tong N.
    Front Endocrinol (Lausanne); 2020 May; 11():599355. PubMed ID: 33335511
    [Abstract] [Full Text] [Related]

  • 18. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ.
    Cardiovasc Diabetol; 2018 Jun 23; 17(1):91. PubMed ID: 29935543
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.